Gene Therapy for CLN2, LX1004, Supported by $100M in Financing

Gene Therapy for CLN2, LX1004, Supported by $100M in Financing

311099

Gene Therapy for CLN2, LX1004, Supported by $100M in Financing

Lexeo Therapeutics announced that it raised $100 million in a financing round to help support the development of pipeline therapies, including LX1004, a potential gene therapy for CLN2 disease, also known as late infantile Batten disease. Other potential treatments supported through this Series B financing include LX2006, a gene therapy for cardiomyopathy associated with Friedreich’s ataxia, and LX1001, a gene therapy for APOE4-associated Alzheimer’s disease, the company announced in a press release. “As we embark on our next…

You must be logged in to read/download the full post.